ReviewCurrent opinion in pharmacology2011
ACE2, a promising therapeutic target for pulmonary hypertension.
Review in Current opinion in pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 101 citations in OpenAlex.
- Mesenchymal stem cell therapy for pulmonary hypertension: an update.Frontiers in bioengineering and biotechnology · 2025Review
- Protection of Qingfei Xieding prescription from idiopathic pulmonary fibrosis by regulating renin-angiotensin and ferroptosis in MLE-12 cells.Histology and histopathology · 2024Article
- A cardiotoxicity-eliminated ACE2 variant as a pan-inhibitor against coronavirus cell invasion.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Article
- Efficacy of Plant-Made Human Recombinant ACE2 against COVID-19 in a Golden Syrian Hamster Model.Viruses · 2023Article
- Role of Angiotensin Converting Enzyme-2 and its modulation in disease: exploring new frontiers.Medicine and pharmacy reports · 2023Review
- Directed evolution of angiotensin-converting enzyme 2 peptidase activity profiles for therapeutic applications.Protein science : a publication of the Protein Society · 2023Article
- A review of cardio-pulmonary microvascular dysfunction in pulmonary hypertension.American heart journal plus : cardiology research and practice · 2023Article
- Intronic regulation of SARS-CoV-2 receptor (ACE2) expression mediated by immune signaling and oxidative stress pathways.iScience · 2022Article
- Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung.Frontiers in immunology · 2022Article
- Review
- Phytoconstituents from ten natural herbs as potent inhibitors of main protease enzyme of SARS-COV-2:Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2021Article
- SARS-CoV-2 infection: Understanding the immune system abnormalities to get an adequate diagnosis.Bosnian journal of basic medical sciences · 2021Review
- The therapeutic potential of the novel angiotensin-converting enzyme 2 in the treatment of coronavirus disease-19.Veterinary world · 2021Review
- Angiotensin-converting enzyme 2 alleviates pulmonary artery hypertension through inhibition of focal adhesion kinase expression.Experimental and therapeutic medicine · 2021Article
- COVID-19 and male reproductive system: pathogenic features and possible mechanisms.Journal of molecular histology · 2021Review
- A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.Drugs in R&D · 2021Article
- A model of the innate immune response to SARS-CoV-2 in the alveolar epithelium.Royal Society open science · 2021Article
- Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor.Sensors and actuators. B, Chemical · 2021Article
- The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response.Biochimie · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a chronic lung disease with poor diagnosis and limited therapeutic options. The currently available therapies are ineffective in improving the quality of life and reducing mortality rates. There exists a clear unmet medical need to treat this disease, which necessitates the discovery of novel therapeutic targets/agents for safe and successful therapy. An altered renin-angiotensin system (RAS) has been implicated as a causative factor in the pathogenesis of PAH. Angiotensin II (Ang II), a key effector peptide of the RAS, can exert deleterious effects on the pulmonary vasculature resulting in vasoconstriction, proliferation, and inflammation, all of which contribute to PAH development. Recently, a new member of the RAS, angiotensin converting enzyme 2 (ACE2), was discovered. This enzyme functions as a negative regulator of the angiotensin system by metabolizing Ang II to a putative protective peptide, angiotensin-(1-7). ACE2 is abundantly expressed in the lung tissue and emerging evidence suggests a beneficial role for this enzyme against lung diseases. In this review, we focus on ACE2 in relation to pulmonary hypertension and provide proof of principle for its therapeutic role in PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.